Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy
- 6 August 2020
- journal article
- editorial
- Published by Wiley in British Journal of Haematology
- Vol. 191 (3), 326-328
- https://doi.org/10.1111/bjh.17031
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution ExperienceClinical Lymphoma Myeloma and Leukemia, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2016
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood, 2016
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesLeukemia & Lymphoma, 2014
- Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletionHaematologica, 2014
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsThe New England Journal of Medicine, 2014
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study GroupJournal of Clinical Oncology, 2012
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010